Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice

Bibliography

• Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516-21
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Auricchio A, Bax J, Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007;28:2803-17
   PubMed Web of Science ®Google Scholar
• Knecht S, Oelschlager C, Duning T, Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-32
   PubMed Web of Science ®Google Scholar
• Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448 e1-19
   PubMedGoogle Scholar
• Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010. [Epub ahead of print]
   PubMedGoogle Scholar
• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-28
   PubMed Web of Science ®Google Scholar
• Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol 2008;52:300-5
   PubMed Web of Science ®Google Scholar
• Kudenchuk PJ, Cobb LA, Copass MK, Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8
   PubMed Web of Science ®Google Scholar
• Dorian P, Cass D, Schwartz B, Amiodarone as compared with lidocaine for shock resistant ventricular fibrillation. N Engl J Med 2002;346:884-90
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354, Erratum in: Circulation 2007;116:e138
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:546S-92S
   PubMedGoogle Scholar
• National Collaborating Centre for Chronic Conditions. Atrial fibrillation: National clinical guideline for management in primary and secondary care. Royal College of Physicians, London; 2006
   Google Scholar
• Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-8
   PubMed Web of Science ®Google Scholar
• Gautier P, Guillemare E, Marion A, Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003;41:191-202
   PubMed Web of Science ®Google Scholar
• Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005;23:217-30
   PubMed Web of Science ®Google Scholar
• Manning AS, Bruyninckx C, Hodeige D, SR 33589: a new amiodarone-like antiarrhythmic agent. Br J Pharmacol 1992;107(Suppl):270P
   Google Scholar
• Bruyninckx C, Ramboux J, Chatelain P, Manning AS. SR 33589, a new amiodarone-like agent: effect on reperfusion-induced arrhythmias in anaesthetised rats. J Mol Cell Cardiol 1992;24(Suppl V):165
   Google Scholar
• Finance O, Manning AS, Chatelain P. SR 33589B, a new amiodarone-like agent: effect on ischaemia-induced ventricular arrhythmias in anaesthetized pigs. Br J Pharmacol 1993;11:28P
   Google Scholar
• Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995;279:25-32
   PubMed Web of Science ®Google Scholar
• Lalevee N, Nargeot J, Barrere-Lemarie S, Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 2003;14:885-90
   PubMed Web of Science ®Google Scholar
• Varro A, Takacs J, Nemeth M, Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 2001;133:625-34
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 1999;100:2276-81
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm 2010;7:1273-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Multaq; Annex I Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001043/WC500044534.pdf
   Google Scholar
• Highlights of prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
   Google Scholar
• Damy T, Pousset F, Caplain H, Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004;18:113-23
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE, Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-91
   PubMed Web of Science ®Google Scholar
• Wadhani N, Sarma JS, Singh BN, Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions. J Cardiovasc Pharmacol Ther 2006;11:184-90
   PubMedGoogle Scholar
• Tschuppert Y, Buclin T, Rothuizen LE, Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-91
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24:1481-7
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, ; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527-9
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, ; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJGM, Van-Eickels M, ; Athena-Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJGM, Torp-Pedersen C, ; for the ATHENA investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174-80
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605
   PubMed Web of Science ®Google Scholar
• Kowey PR, Singh BN. Dronedarone in patients with implantable defibrillators. Heart Rhythm Society 2004 Scientific Session, Late Breaking Clinical Trials Oral Presentation, 22 May 2004: San Francisco, CA
   Google Scholar
• Duray GZ, Schmitt J, Hohnloser SH. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. J Cardiovasc Pharmacol Ther 2010. [Epub ahead of print]
   Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, ; ATHENA Investigators. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010;31:1717-21
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration drug aproval package. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000TOC.cfm
   Google Scholar
• Nice dronedarone appraisal. National Institute for Health and Clinical Excellence Final appraisal determination – Dronedarone for the treatment of non-permanent atrial fibrillation Issue date: July 2010
   Google Scholar